Refractory nephrotic syndrome application of rituximab has a certain therapeutic effect, but the specific therapeutic effect has some individual differences. Rituximab utilizes complement-dependent cytotoxicity and antibody-dependent cytotoxicity to deplete the body’s B-cells and regulate the interaction between the body’s B-cells and T-cells, so as to effectively prevent the relapse and deterioration of refractory nephrotic syndrome in patients. According to the results of clinical trials, rituximab can achieve remission in some high-risk patients with refractory nephrotic syndrome without treatment-related adverse events. This product is contraindicated in patients who are allergic to rituximab, have severe infections, have heart failure, and are pregnant and breastfeeding. Headache, pruritus, throat irritation, flushing, rash, urticaria, hypertension and fever may occur in some patients with this product. Patients with refractory nephrotic syndrome should go to the hospital in time and choose the appropriate medication under the doctor’s guidance to avoid further progression of the disease.